Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Measles Indication Strategy Report 2026: Measles H protein, Trials and Deals
23 July 2026
2026 Measles strategy: epidemiology, Measles H protein biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Rabies Indication Strategy Report 2026: Rabies G protein, Trials and Deals
23 July 2026
2026 Rabies strategy: epidemiology, Rabies G protein biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Yellow fever Indication Strategy Report 2026: YFV E protein, Trials and Deals
23 July 2026
2026 Yellow fever strategy: epidemiology, YFV E protein biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Tick-borne encephalitis Indication Strategy Report 2026: TBEV E protein, Trials and Deals
23 July 2026
2026 Tick-borne encephalitis strategy: epidemiology, TBEV E protein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Japanese encephalitis Indication Strategy Report 2026: JEV E protein, Trials and Deals
23 July 2026
2026 Japanese encephalitis strategy: epidemiology, JEV E protein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
West Nile virus infection Indication Strategy Report 2026: West Nile E protein, Trials and Deals
23 July 2026
2026 West Nile virus infection strategy: epidemiology, West Nile E protein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hantavirus pulmonary syndrome Indication Strategy Report 2026: Hantavirus Gn, Trials and Deals
23 July 2026
2026 Hantavirus pulmonary syndrome strategy: epidemiology, Hantavirus Gn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Crimean-Congo hemorrhagic fever Indication Strategy Report 2026: CCHFV glycoprotein, Trials and Deals
23 July 2026
2026 Crimean-Congo hemorrhagic fever strategy: epidemiology, CCHFV glycoprotein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lassa fever Indication Strategy Report 2026: Lassa GP, Trials and Deals
23 July 2026
2026 Lassa fever strategy: epidemiology, Lassa GP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Ebola virus disease Indication Strategy Report 2026: Ebola GP, Trials and Deals
23 July 2026
2026 Ebola virus disease strategy: epidemiology, Ebola GP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Marburg virus disease Indication Strategy Report 2026: Marburg GP, Trials and Deals
23 July 2026
2026 Marburg virus disease strategy: epidemiology, Marburg GP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nipah virus disease Indication Strategy Report 2026: Nipah G protein, Trials and Deals
23 July 2026
2026 Nipah virus disease strategy: epidemiology, Nipah G protein biology, clinical competition, recent deals, unmet need and market attractiveness.